Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Protagonist Therapeutics stock

Learn how to easily invest in Protagonist Therapeutics stock.

Protagonist Therapeutics Inc is a biotechnology business based in the US. Protagonist Therapeutics shares (PTGX) are listed on the NASDAQ and all prices are listed in US Dollars. Protagonist Therapeutics employs 116 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Protagonist Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PTGX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Protagonist Therapeutics stock price (NASDAQ: PTGX)

Use our graph to track the performance of PTGX stocks over time.

Protagonist Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$29.33
52-week range$12.80 - $50.54
50-day moving average $33.91
200-day moving average $35.78
Wall St. target price$53.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.43

Buy Protagonist Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Stocks
$0
0%
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$0
$1 per month
$5
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Public
Stocks, ETFs, Cryptocurrency
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Protagonist Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Protagonist Therapeutics price performance over time

Historical closes compared with the close of $29.33 from 2022-01-21

1 week (2022-01-14) -18.44%
1 month (2021-12-20) N/A
3 months (2021-10-22) -5.26%
6 months (2021-07-23) -37.62%
1 year (2021-01-22) 31.17%
2 years (2020-01-23) 294.75%
3 years (2019-01-23) 263.00%
5 years (2017-01-23) 65.05%

Protagonist Therapeutics financials

Revenue TTM $24.4 million
Gross profit TTM $28.6 million
Return on assets TTM -22.79%
Return on equity TTM -43.08%
Profit margin 0%
Book value $6.92
Market capitalisation $1.7 billion

TTM: trailing 12 months

Protagonist Therapeutics share dividends

We're not expecting Protagonist Therapeutics to pay a dividend over the next 12 months.

Protagonist Therapeutics share price volatility

Over the last 12 months, Protagonist Therapeutics's shares have ranged in value from as little as $12.8 up to $50.54. A popular way to gauge a stock's volatility is its "beta".

PTGX.US volatility(beta: 2.16)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Protagonist Therapeutics's is 2.1566. This would suggest that Protagonist Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Protagonist Therapeutics overview

Protagonist Therapeutics, Inc. , a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Frequently asked questions

What percentage of Protagonist Therapeutics is owned by insiders or institutions?
Currently 1.143% of Protagonist Therapeutics shares are held by insiders and 102.395% by institutions.
How many people work for Protagonist Therapeutics?
Latest data suggests 116 work at Protagonist Therapeutics.
When does the fiscal year end for Protagonist Therapeutics?
Protagonist Therapeutics's fiscal year ends in December.
Where is Protagonist Therapeutics based?
Protagonist Therapeutics's address is: 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160
What is Protagonist Therapeutics's ISIN number?
Protagonist Therapeutics's international securities identification number is: US74366E1029
What is Protagonist Therapeutics's CUSIP number?
Protagonist Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74366E102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site